Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REEF-1
2019-000622-22Phase 2Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2019
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tomligisiran, bersacapavir, entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide in Chronic Hepatitis B (CHB) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of participants meeting NA treatment completion criteria at Week 48. Status: unknown.
02
Drugs
tomligisiranbersacapavirentecavirtenofovir disoproxil fumaratetenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2019-000622-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000622-22.